Heritable human germline gene editing — altering the DNA of an embryo, egg, or sperm in a way that passes to future generations — sits under a different legal regime than somatic gene editing or standard embryo research. This guide surveys the current legal and regulatory status of clinical heritable germline editing across the jurisdictions research administrators most often need to answer questions about: the United States, the United Kingdom, China, and the international governance layer coordinated through the World Health Organization. It focuses specifically on legal status — who is permitted to do what, under which statute or regulation, and what the penalties are for non-compliance. For the underlying bioethics debate, the 2018 He Jiankui case, and how institutional oversight of germline research actually works day to day, see CASRAI’s companion guide, CRISPR Ethics: Germline Editing, He Jiankui, and Oversight.
The regulatory baseline: no jurisdiction currently permits clinical heritable germline editing
As of this writing, no country has a legal pathway for using CRISPR or any other gene-editing technology to create a pregnancy from a heritably edited human embryo. Coverage varies in mechanism — some jurisdictions rely on criminal statute, others on funding restrictions, others on embryo-research licensing law — but the practical effect converges: clinical use is prohibited or functionally unreachable everywhere it has been examined. Basic, non-heritable research on embryos in vitro (not implanted, destroyed by a legal deadline) is treated very differently and is permitted, under license, in a number of these same jurisdictions. Distinguishing “researching heritable editing techniques in a dish” from “implanting an edited embryo to create a pregnancy” is the single most important line running through every regime described below.
United States: two separate funding riders, not a standalone statute
The US has no single federal law that names and bans heritable human germline editing. Instead, the practical prohibition rests on two distinct appropriations riders that Congress has renewed annually rather than a permanent statute — a distinction that matters because a rider lapses if a future appropriations act omits it, whereas standalone legislation would not.
- The Dickey-Wicker Amendment (first attached in 1996, renewed every year since) bars the Department of Health and Human Services, including the NIH, from using appropriated funds for research in which human embryos are created for research purposes or destroyed, discarded, or knowingly subjected to risk of injury greater than allowed for research on fetuses in utero. This blocks federal funding of embryo research broadly; it is not germline-specific but sweeps in germline embryo research as a subset.
- The FDA appropriations rider, first attached to the Consolidated Appropriations Act for FY2016 and renewed in every subsequent FDA spending bill, separately bars the FDA from using any of its funds to review or approve an application for investigational use of a drug or biological product “in which a human embryo is intentionally created or modified to include a heritable genetic modification.” Because any clinical use of a gene-editing product in the US requires FDA review under an Investigational New Drug application, this rider has the practical effect of closing the regulatory pathway to clinical heritable editing entirely, regardless of what a state or private funder might otherwise allow.
Together, these two riders mean heritable germline editing cannot be federally funded as research and cannot legally reach a clinical trial or product review in the US, even using private funding, for as long as both riders keep being renewed. There is no US state-level workaround for the FDA rider specifically, since FDA jurisdiction over investigational products is federal.
United Kingdom: licensing regime under the HFEA, not a criminal ban
The UK regulates human embryo research and treatment through the Human Fertilisation and Embryology Act 1990, as substantially amended by the Human Fertilisation and Embryology Act 2008, administered by the Human Fertilisation and Embryology Authority (HFEA). Under this framework, essentially all use of human embryos outside the body — research, storage, and treatment — requires an HFEA licence, and embryo research licences are capped at 14 days of development, after which the embryo must be destroyed rather than allowed to develop further or be implanted.
Critically, the HFE Act does not permit implanting a genetically altered embryo for the purpose of establishing a pregnancy. Research groups (including the Francis Crick Institute) have held HFEA licences to study early embryo development using gene editing, but strictly under the research-only, 14-day, no-transfer conditions — the edited embryos are not, and under current law cannot be, implanted. The UK’s separate, narrower allowance for mitochondrial donation techniques (permitted under 2015 regulations made under the HFE Act, for a specific class of mitochondrial disease) is sometimes confused with nuclear-genome germline editing; it is a distinct, much more limited exception and does not extend to CRISPR-style editing of nuclear DNA. The HFEA has periodically consulted on modernising its regulatory framework more broadly, but no consultation has produced a change to the prohibition on implanting a genome-edited embryo.
China: a criminal-law prohibition adopted directly in response to the He Jiankui case
China’s regulatory posture on heritable germline editing changed materially after the 2018 He Jiankui case, in which He claimed to have used CRISPR to edit the CCR5 gene in twin embryos that were then implanted and brought to term. Prior to 2018, China’s oversight relied primarily on non-binding ethical guidelines from bodies such as the then-National Health and Family Planning Commission; He’s prosecution (a three-year prison sentence and a fine, handed down in December 2019) proceeded under a combination of existing regulations rather than a purpose-built criminal statute, which was widely seen as a gap.
China closed that gap with the Eleventh Amendment to the Criminal Law of the People’s Republic of China, which took effect March 1, 2021. It created a specific criminal offense for implanting gene-edited or cloned human embryos into a human or animal body, carrying a sentence of three to seven years’ imprisonment plus fines. This makes China’s current legal regime among the most explicit in the world on this specific act — a dedicated criminal offense, rather than a funding restriction or a licensing-law gap — enacted directly in response to the 2018 case.
International governance: WHO’s framework and registry, not a binding treaty
There is no binding international treaty that governs heritable germline editing globally; oversight is currently a patchwork of national law layered under a set of coordinating, non-binding international instruments.
- The World Health Organization convened an Expert Advisory Committee on Developing Global Standards for Governance and Oversight of Human Genome Editing beginning in December 2018, in direct response to the He Jiankui case. In July 2021, WHO published Human Genome Editing: A Framework for Governance together with companion recommendations and an accompanying position paper, which recommends against any clinical application of heritable human genome editing at this time and sets out governance mechanisms institutions and regulators can adopt.
- WHO also maintains a Human Genome Editing Registry, built on the WHO International Clinical Trials Registry Platform (ICTRP) infrastructure, intended to provide a transparent, centralized record of human genome editing research, with the stated aim of extending to research on embryos and germline cells intended for reproductive use.
- Regional instruments add further, more binding layers in some places: the Council of Europe’s Convention on Human Rights and Biomedicine (the Oviedo Convention) prohibits, for its states parties, any intervention seeking to introduce a modification in the genome of descendants (Article 13). Not every European state has ratified it (notably, the UK has not), so its binding force varies by country even within Europe.
The practical effect of this layer is normative and coordinating rather than directly enforceable: WHO’s framework and registry create a shared international expectation against clinical heritable editing and a mechanism for visibility into ongoing research, but enforcement remains entirely a matter of each country’s own law — which is precisely why the country-by-country detail above is what actually determines legal exposure for a given research program.
What this means for research administrators and compliance offices
For an institution with any cross-border genome-editing research activity, three practical points follow from the status described above:
- “No federal law” is not the same as “no legal barrier” — in the US specifically, the operative prohibitions are annually-renewed appropriations riders, not permanent statute; a compliance office tracking heritable-editing research should track the FDA and Labor-HHS appropriations cycle, not assume the current restriction is fixed law.
- Jurisdiction follows where the embryo is created, edited, and implanted, not necessarily where the sponsoring institution is based — a US-based research program collaborating with a site in a jurisdiction with a different regime needs its own legal review of that jurisdiction’s law, since US funding restrictions do not automatically export to a foreign site’s own permissibility.
- Research-only, non-implantation embryo editing is a different regulatory question from heritable clinical editing in every jurisdiction surveyed here — an IRB, embryology licensing body (such as the HFEA), or institutional biosafety committee reviewing a germline-editing research protocol needs to confirm which category the proposed work actually falls into, since the legal and licensing requirements differ substantially between the two.
For the ethical framework underlying these legal regimes — including the somatic-versus-germline distinction that determines which rules apply at all, and how institutional oversight bodies actually evaluate germline-editing research proposals — see CASRAI’s CRISPR Ethics guide. For the institutional structures (IRBs, research ethics committees) that review human embryo and human subjects research more broadly, see the Human Subjects Protection & Research Ethics hub.
Frequently asked questions
Is CRISPR germline editing illegal everywhere?
No single global law bans it, but every jurisdiction examined in this guide — the US, UK, and China, plus the norm-setting layer coordinated by WHO — currently prohibits or forecloses clinical use through some combination of funding restriction, licensing law, or criminal statute. No country currently offers a legal pathway to implant a heritably edited embryo for the purpose of creating a pregnancy.
Is research-only germline editing (not implanted) also illegal?
Generally not, where properly licensed. The UK permits it under an HFEA research licence limited to 14 days of embryo development with no transfer for pregnancy; similar research-only, non-implantation work occurs under institutional and (in the US) Dickey-Wicker-constrained privately funded review elsewhere. It is the implantation step — creating a pregnancy from an edited embryo — that triggers the strictest prohibitions across all three jurisdictions covered here.
Could the US federal restriction on heritable germline editing change?
Because the FDA rider and the Dickey-Wicker Amendment are appropriations riders rather than standalone statute, they must be renewed in each annual spending bill. They have been renewed every year since first enacted (Dickey-Wicker since 1996, the FDA rider since FY2016), but that renewal is not automatic or legally permanent, which is a meaningfully different footing than the UK’s or China’s law-based prohibitions.
What happened to He Jiankui, and did his case change the law?
He Jiankui was sentenced to three years in prison and fined by a Chinese court in December 2019 for illegal medical practice, after using CRISPR on embryos that were implanted and resulted in the birth of twins in 2018. His case directly prompted both China’s 2021 Criminal Law Eleventh Amendment (creating a specific criminal offense for implanting gene-edited embryos) and WHO’s 2018-2021 global governance framework process. See CASRAI’s CRISPR Ethics guide for the full account of the case and the international reaction it triggered.
